In 2011, the Sunday Times Virgin Fast Track 100 recognised Clinigen as the fastest growing private company in the UK. Hear from their Chief Operating Officer, Debra Ainge on how they managed their growth, difficulties faced during their expansion and her advice for companies looking to expand and enter new markets.
Clinigen (Clinigen Group) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines to improve the quality of people's lives around the world.
We are the global leading experts, trusted by both pharmaceutical and biotech companies and healthcare professionals, in providing access to medicines throughout the lifecycle of a medicine; clinical trials, unlicensed and commercial supply.
Clinigen’s mission is to deliver the right medicine to the right patient at the right time operating in three areas of global medicine supply: clinical trials, unlicensed and licensed medicines.
Operating in a complex regulatory environment, Clinigen is the only company to globally manage access to medicine across all three routes worldwide. We understand the complex challenges facing Pharmaceutical and Biotech companies and are uniquely placed to provide the solutions to help.
Clinigen add insight, expertise and value at every stage of a product’s lifecycle, supporting pharmaceutical companies and healthcare professionals from clinical trials, unlicensed supply and full commercialisation of medicines. That is why, for over 30 years, Clinigen has been trusted by industry and healthcare providers to enable access to more innovative medicines, in more countries, for more patients than anyone else.
As Chief Operating Officer of Clinigen, Debra oversees the key functions that underpin the Group's central operating platform.
Debra joined Clinigen in 2011 as Head of Project Management in Clinigen Managed Access and has held various roles since then, most recently Director of Corporate Projects where she oversaw the acquisitions and integration of Idis and Link Healthcare. Before joining Clinigen she worked in a variety of research and development roles within AstraZeneca. She has 20 years’ experience in the pharmaceutical sector in both large and small/mid-size organisations including R&D, Speciality and Service Pharma. Debra holds a degree and PhD from Newcastle University, and completed post-doctoral studies at the University of Lausanne.
Please note Speaker Breakfast events are free for Patrons and 1813 Club members. When booking, please use your membership number to validate the free places.